Publication:
Systemic treatment of renal cell cancer: A comprehensive review

Simple item page
dc.contributor.authorSanchez-Gastaldo, Amparo
dc.contributor.authorKempf, Emmanuelle
dc.contributor.authorGonzalez del Alba, Aranzazu
dc.contributor.authorDuran, Ignacio
dc.date.accessioned2024-07-11T09:07:21Z
dc.date.available2024-07-11T09:07:21Z
dc.date.issued2017-11
dc.description.abstractKidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.en
dc.format.page77-89es_ES
dc.format.volume60es_ES
dc.identifier.citationSanchez-Gastaldo A, Kempf E, Gonzalez Del Alba A, Duran I. Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treat Rev. 2017 Nov;60:77-89. Epub 2017 Sep 1.en
dc.identifier.doi10.1016/j.ctrv.2017.08.010
dc.identifier.e-issn1532-1967es_ES
dc.identifier.issn0305-7372
dc.identifier.journalCancer Treatment Reviewses_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/17290
dc.identifier.pubmedID28898679es_ES
dc.identifier.puiL618208952
dc.identifier.scopus2-s2.0-85029102409
dc.identifier.urihttp://hdl.handle.net/20.500.12105/20384
dc.identifier.wos416192100010
dc.language.isoengen
dc.publisherElsevier
dc.relation.publisherversionhttps://dx.doi.org/10.1016/j.ctrv.2017.08.010en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectRenal cell cancer
dc.subjectTargeted therapy
dc.subjectAngiogenesis
dc.subjectMonoclonal antibody
dc.subjectTyrosine-kinase inhibitor
dc.subjectmTOR inhibitor
dc.subjectImmunotherapy
dc.subject.decsAntineoplásicos*
dc.subject.decsHumanos*
dc.subject.decsInmunoterapia*
dc.subject.decsTerapia Molecular Dirigida*
dc.subject.decsCarcinoma de Células Renales*
dc.subject.decsNeoplasias Renales*
dc.subject.meshCarcinoma, Renal Cell*
dc.subject.meshImmunotherapy*
dc.subject.meshMolecular Targeted Therapy*
dc.subject.meshKidney Neoplasms*
dc.subject.meshHumans*
dc.subject.meshAntineoplastic Agents*
dc.titleSystemic treatment of renal cell cancer: A comprehensive reviewen
dc.typereview articleen
dspace.entity.typePublication
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Collections

IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)
IBIS - Instituto de Biomedicina de Sevilla (Andalucía)